Astellas's First-In-Class CLDN18 Antibody Meets Phase III Gastric Endpoints

Competitive Advantage Vs Opdivo?

 
• By Lisa Takagi
ZOLBETUXIMAB CAN BECOME A FIRST CANDIDATE TO REACH MARKET AS CLDN18 ANTIBODY
ZOLBETUXIMAB COULD BECOME FIRST ANTI-CLDN18 ANTIBODY TO REACH MARKET • Source: Shutterstock

More from Anticancer

More from Therapy Areas